Enorama Pharma AB (publ) Explores Divestment of Nicotine Replacement Therapy Chewing Gum Business

The board of directors at Enorama Pharma AB (“Enorama Pharma” or the “Company”) has decided to explore the possibility of divesting the part of the business developing and selling its nicotine replacement therapy (“NRT”) chewing gum, to focus on the continued expansion of its NIC-S nicotine pouch product line.   Enorama Pharma has developed a patented range of NRT chewing gums in two strengths and two flavors, featuring superior gum characteristics. The product is already registered in seven European countries. Former CEO Annette Agerskov will lead the divestment process.   “I